Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Paul Dougherty

Paul Dougherty

Dougherty Laser Vision, USA

Title: Topographically-guided laser-in-situ keratomileusis for myopia using a customized aspheric treatment zone

Biography

Biography: Paul Dougherty

Abstract

Abstract Purpose: To assess the efficacy, predictability, safety and quality-of-life effects of topography- guided laser in situ keratomileusis (LASIK) for the correction of myopia with astigmatism using the EC-5000 CXII excimer laser equipped with a customized aspheric treatment zone algorithm.

Setting: Ophthalmology clinics in the United States and Mexico.

Methods: In a multicenter United States Food and Drug Administration study of topography- guided LASIK, 4 centers enrolled 135 eyes with a spherical manifest refraction error ranging from -0.50 to -7.00 diopters (D) and astigmatism ranging from 0.50 to 4.00 D. All eyes were targeted for emmetropia. Refractive outcomes, higher-order aberrations (HOAs), and contrast sensitivity were analyzed preoperatively and postoperatively. Patient satisfaction was assessed using 2 questionnaires.

Results: Six months postoperatively, the mean manifest refraction spherical equivalent in all eyes was -0.09 ± 0.31 (SD); of the 131 eyes, 116 (88.55%) had an uncorrected visual acuity of 20/20 or better and 122 (93.13%) had an MRSE within +0.50 D. The best spectacle-corrected visual acuity (BSCVA) increased by 2 or more lines in 21 (16.03%) of 131 eyes; no eye lost 2 lines or more of BSCVA. The total ocular HOA increased by 0.04 mm. Patients reported significantly fewer night driving and glare/halo symptoms postoperatively than preoperatively.

Conclusion: Use of a customized aspheric treatment zone in eyes with myopia and astigmatism was safe, effective and predictable and reduced symptoms associated with night driving, glare and halos.